MapLight Therapeutics, Inc. (MPLT)
$8.83-3.50%Close
BUYCRISIS · day 19
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $7M
- Beta
- 2.77
- P/E (TTM)
- -1.87
- Short % float
- 1048.35%
- Days to cover
- 5.8
- SI change
- -4.5%
- 1W
- -10.08%
- 1M
- -35.97%
- vs SPY 1W
- -11.24%
- vs SPY 1M
- -38.96%
Industry peers
FMP comparable companies · ranked by market cap
- DFTXSELLDefinium Therapeutics, Inc.$4.9BBEARQ 26$36.90+7.96%
- RAPPSELLRapport Therapeutics, Inc. Common Stock$1.5BCRISISQ 26$30.65+2.68%
- GHRSSELLGH Research PLC$1.4BCRISISQ 16$21.11+3.23%
- LBRXSELLLB Pharmaceuticals Inc Common Stock$1.1BCRISISQ 80$37.22+7.54%
- ANROSELLAlto Neuroscience, Inc.$855MCRISISQ 17$24.37+1.41%
- ZVRASELLZevra Therapeutics, Inc.$673MRECOVERYQ -7$11.39+3.55%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on MPLT?
- LOPJLB’s latest quantitative signal on MapLight Therapeutics, Inc. (MPLT) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is MPLT in?
- MapLight Therapeutics, Inc. (MPLT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does MapLight Therapeutics, Inc. (MPLT) do?
- MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer'…